Allogene Therapeutics (ALLO)
(Real Time Quote from BATS)
$2.54 USD
+0.04 (1.60%)
Updated Jun 3, 2024 02:38 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
Allogene Therapeutics, Inc. [ALLO]
Reports for Purchase
Showing records 101 - 120 ( 215 total )
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New ALLO-501(A) and ALLO-715 Data at ASH; 2Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: Several Updates in 4Q21; Myeloma is Quite Important
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Durable Responses Reported with Allogeneic CAR-T
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Virtual CD19 Forum to Answer ALLO-501(A) Queries; 1Q21 Financials; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21: Will May 19th Address the Durability for ALLO-501 program?
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ALLO-715 Gets Regenerative Medicine Advanced Therapy Designation; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department